AI Engines For more Details: Perplexity Kagi Labs You
Local Anesthesia: Prilocaine acts as a local anesthetic by blocking nerve impulses from sensory nerves, thereby inhibiting the transmission of pain signals to the brain. It is commonly used for procedures such as dental work, minor surgeries, dermatological procedures, and certain medical interventions.
Onset and Duration: Prilocaine typically has a rapid onset of action, with effects usually felt within a few minutes after administration. The duration of anesthesia varies depending on the concentration of the prilocaine solution and the specific formulation used. In general, prilocaine provides local anesthesia for a duration ranging from one to several hours.
Adverse Reactions: While prilocaine is generally considered safe when used appropriately, it can cause side effects in some individuals. Common side effects may include temporary numbness, tingling, or a burning sensation at the site of administration. These side effects are usually mild and transient.
Methemoglobinemia: One of the most significant adverse effects associated with prilocaine is the potential for methemoglobinemia, a rare but serious condition characterized by elevated levels of methemoglobin in the blood. Methemoglobinemia can lead to tissue hypoxia and symptoms such as cyanosis (bluish discoloration of the skin), shortness of breath, dizziness, and fatigue. Risk factors for methemoglobinemia include high doses of prilocaine, co-administration with other medications that can induce methemoglobinemia (such as certain antibiotics), and certain medical conditions (such as glucose-6-phosphate dehydrogenase deficiency).
Monitoring: Healthcare providers should monitor patients receiving prilocaine for signs and symptoms of methemoglobinemia, particularly in high-risk individuals. Prompt recognition and management of methemoglobinemia are essential for preventing complications.
Contraindications: Prilocaine is contraindicated in individuals with a known hypersensitivity to prilocaine or other local anesthetics of the amide type. It should also be used with caution in patients with preexisting methemoglobinemia or hemoglobinopathies.
Drug Interactions: Prilocaine may interact with other medications, particularly those that can induce methemoglobinemia or affect its metabolism. Healthcare providers should assess potential drug interactions and adjust dosages accordingly when prescribing prilocaine.
Rank | Probiotic | Impact |
---|---|---|
species | Bifidobacterium adolescentis | Reduces |
species | Bifidobacterium longum | Reduces |
species | Escherichia coli | Reduces |
subspecies | Bifidobacterium longum subsp. infantis | Reduces |
subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0.4 | 0.4 | |
Acne | 0.3 | -0.3 | |
ADHD | 3.4 | 0.7 | 3.86 |
Age-Related Macular Degeneration and Glaucoma | 0.5 | 0 | 0 |
Allergic Rhinitis (Hay Fever) | 1.1 | 1.7 | -0.55 |
Allergies | 4.5 | 1.1 | 3.09 |
Allergy to milk products | 0.9 | 0.6 | 0.5 |
Alopecia (Hair Loss) | 1 | 1 | |
Alzheimer's disease | 3.1 | 4.2 | -0.35 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.8 | 0.4 | 3.5 |
Ankylosing spondylitis | 2.6 | 1.2 | 1.17 |
Anorexia Nervosa | 0 | 1.5 | 0 |
Antiphospholipid syndrome (APS) | 1.6 | 0.4 | 3 |
Asthma | 1.6 | 0.4 | 3 |
Atherosclerosis | 1.3 | 1.2 | 0.08 |
Atrial fibrillation | 2.2 | 1.4 | 0.57 |
Autism | 6.6 | 6.3 | 0.05 |
Barrett esophagus cancer | 0.6 | 0.1 | 5 |
benign prostatic hyperplasia | 0.2 | 0.2 | |
Bipolar Disorder | 0.8 | 1.2 | -0.5 |
Brain Trauma | 0.8 | 0.4 | 1 |
Carcinoma | 2.9 | 1.7 | 0.71 |
Celiac Disease | 1.3 | 2.8 | -1.15 |
Cerebral Palsy | 0.9 | 0.7 | 0.29 |
Chronic Fatigue Syndrome | 4.1 | 3.5 | 0.17 |
Chronic Kidney Disease | 1.3 | 1.9 | -0.46 |
Chronic Lyme | 0.4 | -0.4 | |
Chronic Obstructive Pulmonary Disease (COPD) | 0.9 | 0.7 | 0.29 |
Chronic Urticaria (Hives) | 1.2 | 0.5 | 1.4 |
Coagulation / Micro clot triggering bacteria | 0.8 | 0.6 | 0.33 |
Colorectal Cancer | 3 | 1.2 | 1.5 |
Constipation | 0.9 | 0.5 | 0.8 |
Coronary artery disease | 1.3 | 0.7 | 0.86 |
COVID-19 | 8.7 | 9.1 | -0.05 |
Crohn's Disease | 6 | 4.1 | 0.46 |
cystic fibrosis | 0.6 | 0.8 | -0.33 |
deep vein thrombosis | 0.6 | 0.4 | 0.5 |
Depression | 7 | 6 | 0.17 |
Dermatomyositis | 0.1 | 0.3 | -2 |
Eczema | 0.8 | 1 | -0.25 |
Endometriosis | 2.1 | 0.5 | 3.2 |
Eosinophilic Esophagitis | 0.4 | 0.2 | 1 |
Epilepsy | 2.3 | 0.8 | 1.87 |
Fibromyalgia | 1.3 | 1.6 | -0.23 |
Functional constipation / chronic idiopathic constipation | 4 | 2.5 | 0.6 |
gallstone disease (gsd) | 1.2 | 1 | 0.2 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.1 | 0.6 | 0.83 |
Generalized anxiety disorder | 1.7 | 1.9 | -0.12 |
giant cell arteritis | 0.3 | -0.3 | |
Glioblastoma | 0.1 | -0.1 | |
Gout | 0.2 | -0.2 | |
Graves' disease | 1.1 | 1.3 | -0.18 |
Halitosis | 0.8 | 0.1 | 7 |
Hashimoto's thyroiditis | 1.4 | 0.9 | 0.56 |
Hidradenitis Suppurativa | 0.9 | 0.2 | 3.5 |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 3 | 0.7 | 3.29 |
hypercholesterolemia (High Cholesterol) | 0.4 | 0.4 | |
hyperglycemia | 0.2 | 0.8 | -3 |
Hyperlipidemia (High Blood Fats) | 0.8 | 0.5 | 0.6 |
hypersomnia | 0.6 | -0.6 | |
hypertension (High Blood Pressure | 1.4 | 3.2 | -1.29 |
Hypothyroidism | 1.3 | -1.3 | |
Hypoxia | 0.2 | 0.2 | |
IgA nephropathy (IgAN) | 2.8 | -2.8 | |
Inflammatory Bowel Disease | 3.1 | 5.7 | -0.84 |
Insomnia | 0.6 | 0.6 | 0 |
Intelligence | 0.5 | 0.2 | 1.5 |
Intracranial aneurysms | 0.5 | 0.5 | 0 |
Irritable Bowel Syndrome | 3.2 | 2 | 0.6 |
Liver Cirrhosis | 3.3 | 2.3 | 0.43 |
Long COVID | 6.5 | 7.4 | -0.14 |
Low bone mineral density | 0.7 | -0.7 | |
Lung Cancer | 0.9 | 0.5 | 0.8 |
ME/CFS with IBS | 0.9 | 2.1 | -1.33 |
ME/CFS without IBS | 2.3 | 1.4 | 0.64 |
Menopause | 1.9 | 1.9 | |
Metabolic Syndrome | 6.8 | 5.1 | 0.33 |
Mood Disorders | 9.1 | 6.5 | 0.4 |
multiple chemical sensitivity [MCS] | 0.3 | 0.2 | 0.5 |
Multiple Sclerosis | 4.2 | 3 | 0.4 |
Multiple system atrophy (MSA) | 0.2 | 0.6 | -2 |
Neuropathy (all types) | 0.4 | 0.2 | 1 |
neuropsychiatric disorders (PANDAS, PANS) | 0.5 | 0.5 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.9 | 4 | -1.11 |
NonCeliac Gluten Sensitivity | 0.3 | -0.3 | |
Obesity | 6 | 2.3 | 1.61 |
obsessive-compulsive disorder | 3.5 | 2.5 | 0.4 |
Osteoarthritis | 1.4 | 0 | 0 |
Osteoporosis | 1.4 | 0.4 | 2.5 |
pancreatic cancer | 0.2 | 0.2 | |
Parkinson's Disease | 2.5 | 3 | -0.2 |
Polycystic ovary syndrome | 1.3 | 1 | 0.3 |
Postural orthostatic tachycardia syndrome | 0.3 | 0.6 | -1 |
Premenstrual dysphoric disorder | 1.1 | 0 | 0 |
primary biliary cholangitis | 0.3 | 0.5 | -0.67 |
Psoriasis | 3.5 | 0.9 | 2.89 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 5.9 | 3 | 0.97 |
Rosacea | 0.4 | 0.5 | -0.25 |
Schizophrenia | 5.1 | 1.4 | 2.64 |
scoliosis | 0.2 | 0.8 | -3 |
Sjögren syndrome | 1.5 | 2 | -0.33 |
Sleep Apnea | 1.2 | 1.4 | -0.17 |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.9 | 0.8 | 0.13 |
Stress / posttraumatic stress disorder | 2.2 | 2.5 | -0.14 |
Systemic Lupus Erythematosus | 3.3 | 1.2 | 1.75 |
Tic Disorder | 0.4 | 1.4 | -2.5 |
Tourette syndrome | 0.2 | -0.2 | |
Type 1 Diabetes | 2.6 | 1.7 | 0.53 |
Type 2 Diabetes | 6.9 | 4.2 | 0.64 |
Ulcerative colitis | 2.1 | 2.9 | -0.38 |
Unhealthy Ageing | 4.8 | 1.7 | 1.82 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.